News and Comments

XOMA: A New Chance for Resurrection?

  Friday, October 02, 2015
  • - Exclusively licenses global rights to its (TGFb) antibody program to Novartis 
  •  More...

EXELIXIS: The Stream Of Good News Continues to Flow

  Monday, September 28, 2015

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced renal cell carcinoma, which was presented at the European Cancer Congress 2015. In the study, Cabozantinib met the primary endpoint of improving progression-free survival as compared to Evorulimus.  More...

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of A Promising Glaucoma Drug

  Thursday, September 17, 2015

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glaucoma.   More...

Huge Improvement in the Differential Diagnosis of Diseases and More

  Wednesday, September 02, 2015

Biotechnology industry is proving to be the most innovative and the most growing among WallStreet industries. Individual biotech companies’ achievements complement each other. Some are evolving the sequencing of genes and genetic analysis, while others are excelling in designing drugs based on the tremendous amount of facts they are getting on root causes of the diseases and the interaction of proteins. The biotech companies have largely improved their drug discovery, design and development, including clinical trial plans and strategies.   More...

Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015


Seres Therapeutics: A novel Approach For Treating Clostridium Difficile infection.

  Friday, August 21, 2015

But First: Here is some Good News From  More...

KITE: News we are Anxious to Hear

  Monday, August 17, 2015

Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms that are designing and developing CAR T Cell immunotherapy treatments for cancer. Many investors are wondering about the plummeting of the stock and obviously others have learned about one death that occurred during clinical trial, which caused KITE selloff.    More...

Inovio is in Much Better Shape than Six Months Ago

  Thursday, August 13, 2015

INOVIO More...

AstraZeneca Selects Mirati Therapeutics Drug For Its cancer Immunotherapy Combination

  Thursday, August 06, 2015

In The NEWS More...

NANTKWEST INC. A Novel Breathtaking Immunotherapy For Cancer?

  Monday, August 03, 2015

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed confident that the stock would surge. As a matter of fact, the stock did surge.    More...

Recent Postings



INNOVIVA (INVA) Incyte (INCY) Ridaforolimus AstraZeneca (AZN) Intermune (ITMN) Editas (EDIT) Micromet (MITI) CompuGen (CGEN) Sanofi (SNY) Theravance (THRX) Theravance Bio Pharma (TBPH) Sangamo (SGMO) Multiple Myeloma Intrexon (XON) Prolor Biotech (PBTH) HALOZYME (HALO) Telaprevir Illumina (ILMN) ISIS (ISIS) Bellicum (BLCM) NOVOCURE (NVCR) Aimmune Therapeutics (AIMT) Mirati Therapeutics (MRTX) IDERA (IDRA) Agenus (AGEN MODERNA Vitae Pharmaceuticals (VTAE) AERIE PHARMACEUTICALS ACADIA (ACAD) Elan (ELN) Biocryst (BCRX) JOUNCE THERAPEUTICS (JNCE) Prosensa (RNA) Ariad (ARIA) Trastuzumab-DM1 Bristol-Myers Squibb (BMY) Biogen Idec (BIIB) Seattle Genetics (SGEN) Sarepta (SRPT) ARGOS (ARGS) ABBVIE (ABBV) REGULUS (RGLS) Velcade (bortezomib) Agenus (AGEN) VANDA (VNDA) Merck (MRK) Ionis (IONS) Galena (GALE) Onyx (ONXX) Herceptin OncoCyte (OCX) PORTOLA (PTLA) Advaxis (ADXS) Dendreon (DNDN) ARCA (ABIO) Auspex (ASPX) CEMPRA (CEMP) Ziofpharm (ZIOP) Inovio (INO) ZALTRAP™ Tysabri AGOS (ARGS) BIOMARIN (BMRN) Dynavax (DVAX) Gilead (GILD) TOKAI (TKAOI) KERYX (KERX) Anacor (ANAC) LEXICON (LXRX) Array Pharmaceuticals (ARRY) Sanofi (SNA) Roche (ROCHE) NEUROCRINE (NBIX) SUNESIS PHARMACEUTICALS (SNSS) Idenix (IDIX) Sequenom (SQNM) Zerenex SERES THERAPEUTICS (MCRB) RenenxBio (RGNX) Amgen (AMGN) Regeneron (REGN) JUNO (JUNO) NANTKWEST (NK) Rapamune GlaxoSmithKline (GSK) ADVENTRIX (ANX) ImmunoGen (IMGN) OSI (OSIP) Human Genome Sciences (HGSI) Alder Biopharmaceuticals (ALDR) Roche (RHHBY) galapagos (GLPG) Valeant Pharmaceuticals International (VRX) Intercept (ICPT) Exelixis (EXEL) Alnylam (ALNY) GUARDIAN HEALTH C4 Therapeutics Sanofi-Aventis (SAN) Vertex (VRTX) Human Longevity (HLI) Anadys (ANDS) PTC Therapeutics (PTCT) Revlimid (lenolidamide) KITE (KITE) CRISPR Therapeutics (CRSP) Jazz Pharmaceuticals (JAZZ) Xoma (XOMA) Endometrial Cancer Abbott Laboratories (ABT) NEKTAR (NKTR)) Cytokinetics (CYTK) Global Cell Therapeutics (GBT) SYNTA (SNTA) Pluristem (PSTI) Ocular Therapeutix (OCUL) Adaptimmune (ADAP) Spike Therapeutics (ONCE) Genentech Benlysta (belimumab)